Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Researchers comparing measures in India study say yes The breakthrough represented by the development and WHO approval in 2010 of the GeneXpert rapid test to detect […]
Analysis shows TB may be sixth highest cause of under-five deaths; toll could be prevented with improved case-finding, diagnosis A study has produced the first estimates […]
Report gives evidence that neurological impacts of Zika go beyond effects on brain development By the time pediatric pathologists explored the cases reported in the August […]
Prolonged persistence of virus has personal, public health, research implications A Liberia-based study published in Open Forum Infectious Diseases has found evidence of Ebola in the […]